Kojima, T., Ogata, T., Ishihara, R., Hara, H., Sun, T., Xu, S., Kato, K. (2025). First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.420